skip to Main Content

Right to Science Submission – October, 2018

The right to enjoy the benefits of scientific progress and its applications is a fundamental human right and one of the central pillars of TAG's advocacy to promote TB research and access to its benefits. The right is enshrined in Article 27 of the Universal Declaration of Human Rights and further articulated in Article 15 of the International Covenant on Economic, Social, and Cultural Rights (ICESCR).
Read more

TB, Human Rights, and Universal Periodic Review

Universal Periodic Review (UPR) is a process through which the human rights record of each United Nations member state is reviewed by other countries every five years. As a civil society organization, TAG regularly writes and submits these UPR reports analyzing the TB situations in UN member states, and you can review our UPR reports on this page.
Read more

White House and Congress Must Boldly Address Drug Pricing and Ensure Access to Critical HIV, HCV, and TB Medications

Treatment Action Group (TAG), NASTAD (National Alliance of State & Territorial AIDS Directors) and HIVMA (HIV Medicine Association join together in submitting collaborative comments today in response to the Department of Health and Human Services (HHS) public request for information (RFI) on the agency’s Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Read more

Letter to Gilead Sciences Opposing Unethical Patient Assistance Program Policy for Truvada for Postexposure Prophylaxis

Gilead Sciences is limiting access to Truvada as a component of nonoccupational postexposure prophylaxis (nPEP) through its patient assistance program to once in a lifetime, with hardship review criteria and processes for subsequent prescriptions that have not been clearly articulated and are likely a considerable barrier to nPEP by uninsured and underinsured U.S. residents.
Read more

US Health & Human Services (HHS) Strategic Plan FY 2018-2022: TAG Comments to the Assistant Secretary for Planning and Evaluation

TAG comments submitted to the Strategic Planning Team at the Office of the Assistant Secretary for Planning and Evaluation regarding the HHS Strategic Plan FY 2018-2022. The HHS Strategic Plan should set a precedent for reducing the burden of disease nationally through its focus on access to affordable treatment, advancement of research, implementation of evidence-based interventions, expansion of populations served, and inclusion of all stakeholders.
Read more
Back To Top